Hunter Syndrome Treatment Market to Reach USD 1,118.4 Million; Increasing Rare Disorders to Fuel Demand for Hunter Syndrome Treatment

The Hunter syndrome treatment market size is predicted to reach USD 1,118.4 million by 2026. The rising need for better treatment will spur opportunities for the Hunter syndrome treatment market in the foreseeable future. Also, the growing demand for advanced therapeutics to treat Hunter syndrome will accelerate the global Hunter syndrome treatment market trends during the forecast period, mentioned in a report, titled “Hunter Syndrome Treatment Market Size, Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)/ Intrathecal), By End User (Hospitals, Specialty Clinics and Others), and Regional Forecast, 2019-2026” the market size stood at USD 702.4 million in 2018 and is predicted to exhibit a CAGR of 6.0% between 2019 to 2026.

Phase II/III Clinical Trials by Shire to Accelerate Market Prospects

The surge in clinics trail by prominent companies can spur demand for rare disease therapeutics, which in turn, will boost the Hunter syndrome treatment market revenue. For instance, Shire plc, Jersey-registered specialty biopharmaceutical company announced the results from its Phase II/III clinical trial evaluating SHP609, previously known as HGT-2310. SHP609 is an investigational formulation of idursulfase administered intrathecally for a new potential indication for the treatment of pediatric patients with Hunter syndrome (mucopolysaccharidosis II or MPS II) and cognitive impairment. Moreover, the growing cases of rare genetic disorder will impel biopharmaceutical companies to initiate clinical trials and launch novel drugs, which in turn will create business opportunities for the market in the forthcoming years. Moreover, the surge in unmet needs of patients will encourage healthy growth of the Hunter syndrome treatment market size.

 To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/hunter-syndrome-treatment-market-102536

Surge in Orphan Disease to Augment Growth

The increasing R&D investments for the development of effective therapies to treat orphan diseases and Hunter syndrome will have a positive impact on the Hunter syndrome treatment market during the forecast period. Moreover, the growing number of orphan disease and rare genetic disease patients will spur demand for Hunter syndrome treatment, thus boosting the market growth. According to the Genetic and Rare Diseases Information Center (GARD), there can be an estimated 7,000 rare diseases and the total number of individuals in the U.S. from these rare diseases can be 25-30 million. As per the U.S. Nation Library of Medicine, Hunter Syndrome also known as MPS II occurs in approximately 1 in 100,000 to 1 in 170,000 males. Moreover, the ongoing pipeline candidates in Phase 1 and 2 by biopharmaceutical companies such as ArmaGen, Denali Therapeutics, and REGENXBIO Inc will propel healthy growth of the market in the forthcoming years. However high cost associated with therapeutics and lower treatment rates will subsequently dampen the growth of the market during the forecast period.

Shire’s Product Offering to Consolidate Market Trajectory

The key players in the market are focused on strengthening their product portfolio and clinical trials for pipeline drugs and therapeutics. Shire is fixed on consolidating the market by offering novel drugs to treat rare diseases.  For instance, product offering of Elaprase (idursulfase) by shire. The therapy is  efficient for treatment outcomes and also its indispensability will fuel demand for rare disease treatment. Moreover, the drug candidate by prominent key players will uplift the Hunter syndrome treatment market share in the foreseeable future. For  instance, in September 2018  ArmaGen, a clinical stage biotechnology company, announced a drug candidate called AGT-182, which is currently in Phase I clinical trials for the ‘safety and dose ranging study of insulin receptor MoAb-IDS fusion protein in patients with Hunter syndrome’.

The Reports Highlights the List of Prominent Companies in the Market:

• Shire (Takeda Pharmaceutical Company Limited)


• Denali Therapeutics


• ArmaGen


• Inventiva


• Green Cross Corp. (GC Pharma)


• CANbridge Life Sciences Ltd.


• JCR Pharmaceuticals Co., Ltd.


• REGENXBIO Inc.

Further Report Findings

• Regional Analysis: The market North America generated a revenue of USD 358.9 million in 2018 and is predicted to grow rapidly during the forecast period owing to the increasing diagnosis and treatment rates for rare disorders. Moreover, the developed healthcare facilities will stimulate healthy growth in the region.


• Leading Segment: Enzyme replacement therapy (ERT) segment dominated the Hunter syndrome therapeutics market share in 2018 and is expected to lead the market during the forecast period due to the availability of the only two therapeutics approved by the regulatory authorities such as Elaprase and Hunterase.

The Hunter Syndrome Treatment Market is Segmented into: